Table 2.
Baseline patient and lesion characteristics by timing of immunotherapy.
| Patient characteristic | Concurrent only (n=33) |
Non- concurrent only (n=22) |
Both concurrent and non- concurrent SRS (n=20) |
p value |
|---|---|---|---|---|
| Mean age at first SRS (yrs) | 64.1 | 61.4 | 61.4 | 0.6765 |
| Sex | ||||
| Male | 24 (73%) | 13 (59%) | 14 (70%) | 0.555 |
| Female | 9 (27%) | 9 (41%) | 6 (30%) | |
| Median KPS | 90 (70-100) | 90 (60-100) | 100 (50-100) | 0.218 |
| Median melanoma-specific GPA | 2 (1-4) | 3 (0-4) | 3 (0-4) | 0.580 |
| History of WBRT before SRS | 3 (9%) | 2 (9%) | 0 (0%) | 0.378 |
| Active systemic disease | 29 (88%) | 16 (73%) | 16 (80%) | 0.363 |
| Median time from initial melanoma diagnosis to development of BrMets (months) |
26.1 (0-229) | 66.2 (0-318) | 51.5 (0-287) | 0.0128 |
| BRAF status* | ||||
| Mutated | 10 (30) | 5 (23) | 7 (35) | 0.601 |
| Wild-type | 17 (52) | 7 (32) | 6 (30) | |
| Prior chemotherapy | 7 (21%) | 11 (50%) | 0 (0%) | <0.0001 |
| BRAF inhibitor | 6 (18%) | 3 (14%) | 6 (30%) | 0.392 |
| Type of immunotherapy | ||||
| Anti-CTLA-4 | 19 (58%) | 19 (86%) | 16 (80%) | 0.043 |
| Anti-PD-1 | 14 (42%) | 3 (14%) | 4 (20%) | |
| Median number of BrMets treated per SRS session |
3 (1-23) | 3 (1-20) | 4 (1-21) | 0.4981 |
| Lesion characteristic | n=313 | n=253 | - | |
| Median lesion volume (mm3) | 112 (4- 10370) |
97.5 (4- 27482) |
- | 0.3176 |
| Median dose (Gy) | 20 (12-24) | 20 (12-24) | - | <0.0001† |
*
not all patients were tested for BRAF status
†
concurrently treated lesions had a lower distribution of marginal doses